Reuters logo
BRIEF-Ablexis says announces perpetual license agreement for AlivaMab Mouse with Janssen
February 14, 2017 / 2:14 PM / 10 months ago

BRIEF-Ablexis says announces perpetual license agreement for AlivaMab Mouse with Janssen

Feb 14 (Reuters) - Ablexis LLC

* Ablexis says non-exclusive license provides Janssen access to AlivaMab Mouse platform, broad rights to use AlivaMab Mouse for antibody drug discovery, development

* Ablexis says will receive an eight-figure up-front payment Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below